Monograph Details
|
|
Nutrition
> Obesity
|
|
PRELU-2 |
| Manufacturer |
|
Roxane Laboratories, Inc. |
| Legal Classification |
|
CIII |
| Pharmacological Class |
|
Sympathomimetic. |
| Generic Name |
|
Phendimetrazine tartrate 105mg; sust rel caps. |
| Indications |
|
Short-term adjunct in management of exogenous obesity. |
| Children |
|
Not recommended. |
| Adults |
|
105mg daily in the morning. |
| Contraindications |
|
Arteriosclerosis. Cardiovascular disease. Hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs. Pregnancy. |
| Precautions |
|
Discontinue after a few weeks as tolerance to anorectic effect occurs. Diabetes. Prescribe limited supply to prevent overdose. |
| Interactions |
|
Hypertensive crisis with MAOIs. Blocks guanethidine. |
| Adverse Reactions |
|
Abuse potential, impairment in hazardous activities, arrhythmias, hypertension, CNS overstimulation, psychosis, dry mouth, GI disturbances, urticaria, primary pulmonary hypertension, valvular heart disease. |
| How Supplied |
|
Caps—100 |
|
|
|
|
